Legal status · United States
Is Dersimelagon legal in the United States?
No. Dersimelagon is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Moderate.
Dersimelagon in the United States at a glance
| Classification | Investigational, not approved |
|---|---|
| FDA approval status | Investigational; Phase 3 met primary endpoint (Fast Track, Orphan) |
| Evidence level | Moderate (research strength: Strong) |
| Reviewed | Sep 2026 |
Classification and note come from the Dersimelagon profile, checked against U.S. Food and Drug Administration (FDA) listings at the reviewed date.
What this means
- 01
Dersimelagon is being studied in registered clinical trials but has not received FDA marketing approval in the United States.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What Dersimelagon is
An oral selective MC1R agonist, a small-molecule cousin of afamelanotide, that met its Phase 3 endpoint in the light-sensitivity disorder erythropoietic protoporphyria in January 2026.
Dersimelagon activates the melanocortin-1 receptor to increase protective skin pigmentation without the broader effects of non-selective melanocortin peptides. The INSPIRE Phase 3 (165 patients, 200 mg daily) met its primary endpoint in erythropoietic protoporphyria and X-linked protoporphyria, and the drug holds Fast Track and Orphan designations.
Mechanism: Selective MC1R agonism stimulating eumelanin production in the skin.
Regulatory history: Investigational; Phase 3 met primary endpoint (Fast Track, Orphan)
How FDA treats this kind of product
Approves prescription drugs by indication and polices unapproved products, including peptides sold online. Compounding pharmacies may prepare some compounds under a prescription when the FDA places them on a permitted bulk-substances category.
The classification above is the The Longevity Archive reading of U.S. Food and Drug Administration listings for Dersimelagon at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
Dersimelagon in other countries
Frequently asked questions
Is Dersimelagon legal in the United States?
No. Dersimelagon is not approved for any medical use in the United States; its classification is "Investigational, not approved". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. Human evidence to date: Moderate.
Can I buy Dersimelagon in the United States?
No approved product exists to buy. In the United States Dersimelagon is classified as "Investigational, not approved", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is Dersimelagon FDA approved?
No. FDA status: Investigational; Phase 3 met primary endpoint (Fast Track, Orphan). Current US classification: "Investigational, not approved". Evidence level: Moderate.
Related compounds in the United States
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for Dersimelagon live on its compound profile.
Dersimelagon profileThis page is general information about the regulatory status of Dersimelagon in the United States, current as of Sep 2026. It is not legal advice, and classifications change; check U.S. Food and Drug Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.